Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

Claim 1 (currently amended): A tablet capable of being chewed or disintegrated in the oral cavity prior to swallowing, comprising a therapeutically effective amount of a pharmaceutically active ingredient~~, and~~ contained in a matrix ~~comprising~~ consisting essentially of from about 15 to about 90 % by weight of directly compressible dextrose monohydrate having an average particle size of about 100 to about 500 microns and about 0.005 to about 10 % by weight of sucralose, the % weight being based on the total weight of said tablet, said tablet is fat-free and said matrix being substantially free of non-saccharide, water soluble polymeric binders.

Claim 2 (original): The tablet of claim 1, wherein the active ingredient is selected from the group consisting of acetaminophen, ibuprofen, pseudoephedrine, dextromethorphan, diphenhydramine, chlorpheniramine, calcium carbonate, magnesium hydroxide, magnesium carbonate, magnesium oxide, aluminum hydroxide, mixtures thereof, and pharmaceutically acceptable salts thereof.

Claim 3 (original): The tablet of claim 1, wherein the directly compressible dextrose monohydrate has an average particle size of about 100 to about 250 microns.

Claim 4 (original): The tablet of claim 1, wherein the weight ratio of dextrose monohydrate to sucralose is at least about 25:1.

Claim 5 (currently amended): The tablet of claim 1 containing about ~~15~~25 to about ~~90~~85 % by weight of dextrose monohydrate based on the total weight of the tablet.

Claims 6-7 (cancelled)

Claim 8 (original): The tablet of claim 1 being substantially free of aspartame.

Claim 9 (original): The tablet of claim 1 wherein the pharmaceutically active ingredient has an average particle size from about 100 to about 500 microns.

Claim 10 (original): The tablet of claim 1 manufactured by a direct compression or dry granulation process.

Claim 11 (original): The tablet of claim 1 being substantially free of microcrystalline cellulose.

Claim 12 (currently amended): A tablet capable of being chewed or disintegrated in the oral cavity prior to swallowing, comprising

a pharmaceutically active ingredient~~, and~~ contained in

a matrix comprising

about 30 to about 75 % by weight of directly compressible dextrose monohydrate;

about 0.005 to about 10 % by weight of sucralose based on the weight of the tablet;

at least one disintegrating agent selected from the group consisting of microcrystalline cellulose, starch, sodium starch glycolate, crosslinked polyvinylpyrrolidone, crosslinked carboxymethylcellulose, and mixtures thereof;

at least one lubricant selected from magnesium stearate, stearic acid, and mixtures thereof;

and optionally an auxiliary ingredient selected from the group consisting of fillers, sweeteners, surfactants, glidants, acidulents, antioxidants, preservatives, coloring, flavoring agents, and mixtures thereof;

said tablet being substantially free of triglycerides and said matrix being substantially free of non-saccharide, water soluble polymeric binders.

Claim 13 (previously presented): The tablet of claim 12 wherein the tablet comprises no more than 25 % by weight of said optional auxiliary ingredients.